General
Preferred name
RADIUM RA 223 DICHLORIDE
Synonyms
Xofigo ()
Radium (223ra) dichloride ()
Radium-223 dichloride ()
Alpharadin ()
Radium chloride ra-223 ()
BAY88-8223 ()
Radium-223 chloride ()
BAY-88-8223 ()
BAY 88-8223 ()
Radium ra-223 dichloride ()
Radium ra223 dichloride ()
Radium chloride (223racl2) ()
P&D ID
PD009172
CAS
444811-40-9
Tags
inorganic
drug
Approved by
FDA
First approval
2013
Drug Status
investigational
approved
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA Radium Ra 223 Dichloride is the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. The high energy damages bone cells by introducing double-stranded DNA breaks. This leads to cell death and prevention of the spread of the bone cancer cells. As well because of the alpha particle's short range of less than 10 cell diameters, its damaging effects would less likely affect the non-cancerous cells nearby. ;
INDICATION Used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant.;
ROE Radium-223 is mainly eliminated through the feces (13%) and to a lesser extent in the urine (2%). It is also noted that the elimination rate of radium-223 from the intestines is variable due to the high variability of intestinal transit rates among patients. Therefore there could be more intestinal radiation exposure in patients with slower intestinal transit rates, but the significance of this in relation to toxicity is not known.; ;
TOXICITY Because of its cytotoxic actions that have a high potential to cause fetal harm, Radium Ra 223 Dichloride is contraindicated in women who are pregnant or are of child bearing age. Other side effects include several hematological lab abnormalities, peripheral edema, nausea, vomiting, and diarrhea.;
METABOLISM Radium-223 does not undergo metabolism because it is a radioisotope that decays.;
HALF-LIFE The half-life is relatively long at 11.4 days for radium-223.;
Compound Sets
6
ChEMBL Approved Drugs
CHEMBL2107816
ChEMBL Drugs
CHEMBL2107816
DrugBank
DB08913
DrugBank Approved Drugs
DB08913
DrugCentral
4800
DrugCentral Approved Drugs
4800
External IDs
11
Properties
(calculated by RDKit )
Molecular Weight
292.96
Hydrogen Bond Acceptors
0
Hydrogen Bond Donors
0
Rotatable Bonds
0
Ring Count
0
Aromatic Ring Count
0
cLogP
1.38
TPSA
0.0
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
0.0
QED
0.63
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Source data